Sugi Predict

Sugi Predict / Compounds / SCHEMBL1229065

SCHEMBL1229065

SCHEMBL1229065

Nc1nc2c([nH]c(=S)n2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 3/20 0.65
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ TLR7 Q9NYK1 2/20 0.55
▸ CYP3A4 P08684 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ APOBEC3G Q9HC16 1/20 0.51
▸ CDK1 P06493 1/20 0.45
▸ HSPA5 P11021 1/20 0.42
▸ HSPA8 P11142 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ MTOR P42345 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ THRB P10828 1/20 0.42
▸ MDM2 Q00987 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GMNN O75496 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23982330 1.00 PNP (0.65) PNPMEN1KMT2ATLR7CYP3A4
SCHEMBL20418973 1.00 PNP (0.65) PNPMEN1KMT2ATLR7CYP3A4
8-Hydroxyguanosine SCHEMBL20419141 0.88 PNP (0.68) PNPMEN1KMT2ATLR7CYP3A4
8-Hydroxyguanosine SCHEMBL29374403 0.88 PNP (0.68) PNPMEN1KMT2ATLR7CYP3A4
8-Hydroxyguanosine SCHEMBL23633218 0.88 PNP (0.68) PNPMEN1KMT2ATLR7CYP3A4
8-Hydroxyguanosine SCHEMBL23982342 0.88 PNP (0.68) PNPMEN1KMT2ATLR7CYP3A4
8-Hydroxyguanosine SCHEMBL114651 0.88 PNP (0.68) PNPMEN1KMT2ATLR7CYP3A4
SCHEMBL3621924 0.87 PNP (0.51) PNPMEN1KMT2ATLR7CYP3A4
SCHEMBL9343760 0.86 PNP (0.65) PNPMEN1KMT2ATLR7CYP3A4
SCHEMBL10006893 0.84 UMPS (0.55) PNPAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598504-A2 MICROPARTICLE AND IMPLANT FORMULATIONS FOR CGMP ANALOG THERAPY Mireca Medicines GmbH (DE) 2025-08-13 — — EP claimed
WO-2024074585-A2 MICROPARTICLE AND IMPLANT FORMULATIONS FOR cGMP ANALOG THERAPY MIRECA MEDICINES GMBH (DE) 2024-04-11 — — WO claimed
EP-0341066-B1 Immunostimulating guanine derivatives, compositions and methods SCRIPPS CLINIC RES (US) 1994-11-09 — — EP claimed
EP-0341066-A2 Immunostimulating guanine derivatives, compositions and methods SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-11-08 — — EP claimed
EP-0341065-A2 Immunostimulating guanine dervatives, compositions and methods SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-11-08 — — EP claimed
EP-4746905-A1 RSV VACCINE Astrazeneca AB (SE) 2026-05-27 — — EP disclosed
WO-2026104647-A1 VACCINE ASTRAZENECA AB (SE) 2026-05-21 — — WO disclosed
US-20260115312-A1 Conjugates for neuroretinal drug delivery MIRECA MEDICINES GMBH (DE) 2026-04-30 — — US disclosed
US-12583882-B2 Equatorially modified polymer linked multimers of guansine-3′, 5′-cyclic monophosphates MIRECA MEDICINES GMBH (DE) 2026-03-24 — — US disclosed
WO-2025125630-A1 METHOD FOR BIOPROTAC DESIGN MEDIMMUNE LIMITED (GB) 2025-06-19 — — WO disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 — — EP disclosed
US-20250041400-A1 RSV VACCINE ASTRAZENECA PHARMACEUTICALS LP 2025-02-06 — — US disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 — — US disclosed
US-5166141-A Antigen specific immunune response by contacting lymphocytes SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1992-11-24 — — US disclosed
US-5136030-A Immunostimulating guanine derivatives, compositions and methods SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1992-08-04 — — US disclosed
US-5093318-A Immunostimulating guanosine derivatives and their pharmaceutical compositions SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1992-03-03 — — US disclosed
US-5011828-A Immunostimulating guanine derivatives, compositions and methods SCRIPPS CLINIC AND RESEARCH FOUNDATION 1991-04-30 — — US disclosed
EP-0343945-A2 Immunostimulating 7-deaza-7-oxa-and 7-deaza-7-thia-analogs of 8-substituted-guanine-9-(1'-beta-d-aldoglycosidyl) derivatives, compositions and methods SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-11-29 — — EP disclosed
EP-0341066-A2 Immunostimulating guanine derivatives, compositions and methods SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-11-08 — — EP disclosed
EP-0341065-A2 Immunostimulating guanine dervatives, compositions and methods SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583882-B2 Equatorially modified polymer linked multimers of guansine-3′, 5′-cyclic monophosphates PDE7A, PRKG1, NT5C3B PNP 14/4885MEN1 3770/4885KMT2A 3091/4885
US-20260115312-A1 Conjugates for neuroretinal drug delivery SLC16A1, SLC16A3, SLC16A8 PNP 4445/4885MEN1 1573/4885KMT2A 2010/4885
US-20250041400-A1 RSV VACCINE LSS, SLFN12, FDPS PNP 1585/4885MEN1 4556/4885KMT2A 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.